Search Results - "LARBOURET, Christel"

Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis by Leconet, Wilhem, Chentouf, Myriam, du Manoir, Stanislas, Chevalier, Clément, Sirvent, Audrey, Aït-Arsa, Imade, Busson, Muriel, Jarlier, Marta, Radosevic-Robin, Nina, Theillet, Charles, Chalbos, Dany, Pasquet, Jean-Max, Pèlegrin, André, Larbouret, Christel, Robert, Bruno

“…AXL receptor tyrosine kinase has been described as a relevant molecular marker and a key player in invasiveness, especially in triple-negative breast cancer…”
Get full text

An auristatin‐based antibody‐drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer by Bourillon, Laura, Bourgier, Céline, Gaborit, Nadège, Garambois, Véronique, Llès, Eva, Zampieri, Alexandre, Ogier, Charline, Jarlier, Marta, Radosevic‐Robin, Nina, Orsetti, Béatrice, Delpech, Hélène, Theillet, Charles, Colombo, Pierre‐Emmanuel, Azria, David, Pèlegrin, André, Larbouret, Christel, Chardès, Thierry

“…Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer characterized by poor response to chemotherapy and radiotherapy due to the lack of efficient…”
Get full text

Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking by Lanotte, Romain, Garambois, Véronique, Gaborit, Nadège, Larbouret, Christel, Musnier, Astrid, Martineau, Pierre, Pèlegrin, André, Chardès, Thierry

“…Human epidermal growth factor receptor 4 (HER4) isoforms have oncogenic or tumor suppressor functions depending on their susceptibility to proteolytic cleavage…”
Get full text

Examination of HER3 targeting in cancer using monoclonal antibodies by Gaborit, Nadège, Abdul-Hai, Ali, Mancini, Maicol, Lindzen, Moshit, Lavi, Sara, Leitner, Orith, Mounier, Lucile, Chentouf, Myriam, Dunoyer, Sai, Ghosh, Manjusha, Larbouret, Christel, Chardès, Thierry, Bazin, Hervé, Pèlegrin, André, Sela, Michael, Yarden, Yosef

“…Significance The human EGF receptor (EGFR/HER) family plays critical roles in tumor progression. Therefore, several therapies intercepting these receptors were…”
Get full text

Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment by Tosi, Diego, Pérez-Gracia, Esther, Atis, Salima, Vié, Nadia, Combès, Eve, Gabanou, Mélissa, Larbouret, Christel, Jarlier, Marta, Mollevi, Caroline, Torro, Adeline, Del Rio, Maguy, Martineau, Pierre, Gongora, Céline

“…The irinotecan-induced phosphokinome changes in colorectal cancer (CRC) cells were used to guide the selection of targeted agents to be tested in combination…”
Get full text

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer by Rabia, Emilia, Garambois, Véronique, Dhommée, Christine, Larbouret, Christel, Lajoie, Laurie, Buscail, Yoan, Jimenez-Dominguez, Gabriel, Choblet-Thery, Sylvie, Liaudet-Coopman, Emmanuelle, Cerutti, Martine, Jarlier, Marta, Ravel, Patrice, Gros, Laurent, Pirot, Nelly, Thibault, Gilles, Zhukovsky, Eugene A, Gérard, Pierre-Emmanuel, Pèlegrin, André, Colinge, Jacques, Chardès, Thierry

“…The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current…”
Get full text

Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3 by Le Clorennec, Christophe, Bazin, Hervé, Dubreuil, Olivier, Larbouret, Christel, Ogier, Charline, Lazrek, Yassamine, Garambois, Véronique, Poul, Marie-Alix, Mondon, Philippe, Barret, Jean-Marc, Mathis, Gérard, Prost, Jean-François, Pèlegrin, André, Chardès, Thierry

“…Exploratory clinical trials using therapeutic anti-HER3 antibodies strongly suggest that neuregulin (NRG1; HER3 ligand) expression at tumor sites is a…”
Get full text

In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption by Larbouret, Christel, Gaborit, Nadège, Chardès, Thierry, Coelho, Mickaël, Campigna, Emmanuelle, Bascoul-Mollevi, Caroline, Mach, Jean-Pierre, Azria, David, Robert, Bruno, Pèlegrin, André

“…Abstract We previously demonstrated the synergistic therapeutic effect of the cetuximab (anti-epidermal growth factor receptor [EGFR] monoclonal antibody,…”
Get full text

ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells by Le Clorennec, Christophe, Lazrek, Yassamine, Dubreuil, Olivier, Sampaio, Carla, Larbouret, Christel, Lanotte, Romain, Poul, Marie-Alix, Barret, Jean-Marc, Prost, Jean-François, Pèlegrin, André, Chardès, Thierry

“…HER3/ErbB3 receptor deletion or blockade leads to tumor cell apoptosis, whereas its overexpression confers anti-cancer drug resistance through upregulation of…”
Get full text

The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation by Le Clorennec, Christophe, Lazrek, Yassamine, Dubreuil, Olivier, Larbouret, Christel, Poul, Marie-Alix, Mondon, Philippe, Melino, Gerry, Pèlegrin, André, Chardès, Thierry

“…We characterized the mechanism of action of the neuregulin-non-competitive anti-HER3 therapeutic antibody 9F7-F11 that blocks the PI3K/AKT pathway, leading to…”
Get full text

Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models by Rabia, Emilia, Garambois, Véronique, Hubert, Julie, Bruciamacchie, Marine, Pirot, Nelly, Delpech, Hélène, Broyon, Morgane, Theillet, Charles, Colombo, Pierre-Emmanuel, Vie, Nadia, Tosi, Diego, Gongora, Celine, Khellaf, Lakhdar, Jarlier, Marta, Radosevic-Robin, Nina, Chardès, Thierry, Pèlegrin, André, Larbouret, Christel

“…Chemoresistance, particularly to gemcitabine, is a major challenge in pancreatic cancer. The epidermal growth factor receptor (EGFR) and human epidermal growth…”
Get full text

STING‐ATF3/type I interferon crosstalk: A potential target to improve anti‐tumour immunity in chemotherapy‐treated urothelial carcinoma by Fauvre, Alexandra, Machu, Margot, Merienne, Audrey, Vie, Nadia, Bessede, Thomas, Robin, Mathilde, Garambois, Veronique, Taffoni, Clara, Laguette, Nadine, Gervois‐Segain, Nadine, Jarry, Anne, Labarriere, Nathalie, Allory, Yves, Larbouret, Christel, Gros, Laurent, Tosi, Diego, Solit, David B., Pourquier, Philippe, Houédé, Nadine, Gongora, Celine

“…Upper Tract Urothelial Carcinomas (UTUC) are extremely aggressive and immunosuppressed tumors of the ureter or renal pelvis with a high relapse rate (>50%)…”
Get full text

Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer by Ho-Pun-Cheung, Alexandre, Bazin, Hervé, Gaborit, Nadège, Larbouret, Christel, Garnero, Patrick, Assenat, Eric, Castan, Florence, Bascoul-Mollevi, Caroline, Ramos, Jeanne, Ychou, Marc, Pèlegrin, André, Mathis, Gérard, Lopez-Crapez, Evelyne

“…Following the development of targeted therapies against EGFR and HER2, two members of the human epidermal receptor (HER) family of receptor tyrosine kinases,…”
Get full text

In vivo Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas by LARBOURET, Christel, ROBERT, Bruno, AZRIA, David, NAVARRO-TEULON, Isabelle, THEZENAS, Simon, LADJEMI, Maha-Zohra, MORISSEAU, Sébastien, CAMPIGNA, Emmanuelle, BIBEAU, Frédéric, MACH, Jean-Pierre, PELEGRIN, André

“…Purpose: Pancreatic carcinoma is highly resistant to therapy. Epidermal growth factor receptor (EGFR) and HER2 have been reported to be both dysregulated in…”
Get full text

Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation by Lazrek, Yassamine, Dubreuil, Olivier, Garambois, Véronique, Gaborit, Nadège, Larbouret, Christel, Le Clorennec, Christophe, Thomas, Gaelle, Leconet, Wilhem, Jarlier, Marta, Pugnière, Martine, Vié, Nadia, Robert, Bruno, Monnet, Céline, Bouayadi, Khalil, Kharrat, Hakim, Mondon, Philippe, Pèlegrin, André, Chardès, Thierry

“…Abstract Blockade of the human epidermal growth factor receptor 3 (HER3) and of the downstream phosphatidylinositide 3-kinase (PI3K)/AKT pathway is a…”
Get full text

MHC Class I–Related Chain A Conjugated to Antitumor Antibodies Can Sensitize Tumor Cells to Specific Lysis by Natural Killer Cells by GERMAIN, Claire, LARBOURET, Christel, CESSON, Valérie, DONDA, Alena, HELD, Werner, MACH, Jean-Pierre, PELEGRIN, André, ROBERT, Bruno

“…Purpose: As a first step for the development of a new cancer immunotherapy strategy, we evaluated whether antibody-mediated coating by MHC class I–related…”
Get full text

Radiocurability by Targeting Tumor Necrosis Factor-α Using a Bispecific Antibody in Carcinoembryonic Antigen Transgenic Mice by Larbouret, Christel, Ph.D, Robert, Bruno, Ph.D, Linard, Christine, Ph.D, Teulon, Isabelle, Ph.D, Gourgou, Sophie, M.Sc, Bibeau, Frederic, M.D, Martineau, Pierre, Ph.D, Santoro, Lore, M.Sc, Pouget, Jean-Pierre, Ph.D, Pelegrin, Andre, Ph.D, Azria, David, M.D., Ph.D

“…Purpose Tumor necrosis factor-α (TNF-α) enhances radiotherapy (RT) killing of tumor cells in vitro and in vivo . To overcome systemic side effects, we used a…”
Get full text

Correction: The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation by Le Clorennec, Christophe, Lazrek, Yassamine, Dubreuil, Olivier, Larbouret, Christel, Poul, Marie-Alix, Mondon, Philippe, Melino, Gerry, Pèlegrin, André, Chardès, Thierry

Get full text

Improving Biologics’ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures by Larbouret, Christel, Gros, Laurent, Pèlegrin, André, Chardès, Thierry

“…Monoclonal antibodies have revolutionized the treatment of many diseases, but their clinical efficacy remains limited in some other cases. Pre-clinical and…”
Get full text

Biasing HER4 tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking by Lanotte, Romain, Garambois, Véronique, Gaborit, Nadège, Larbouret, Christel, Musnier, Astrid, Martineau, Pierre, Pèlegrin, André, Chardès, Thierry

“…Human epidermal growth factor receptor 4 (HER4) isoforms have oncogenic or tumor suppressor functions depending on their susceptibility to proteolytic cleavage…”
Get full text